Immunotherapy advances in uro-genital malignancies

详细信息    查看全文

• 作者：Raffaele Ratta^aAuthor Vitae ; Roberta Zappasodi^bAuthor Vitae ; Daniele Raggi^aAuthor Vitae ; Paolo Grassi^aAuthor Vitae ; Elena Verzoni^aAuthor Vitae ; Andrea Necchi^aAuthor Vitae ; Massimo Di Nicola^cAuthor Vitae ; Roberto Salvioni^dAuthor Vitae ; Filippo de Braud^aAuthor Vitae ; Giuseppe Procopio^a ; ^{giuseppe.procopio@istitutotumori.mi.it" class="auth_mail" title="E-mail the corresponding author}Author Vitae
• 关键词：Cancer immunotherapy ; Monoclonal antibodies ; Renal cell carcinoma ; Prostate cancer ; Urothelial cancer ; Immune checkpoint inhibitors ; CTLA-4 ; PD-1
• 刊名：Critical Reviews in Oncology and Hematology
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：105
• 期：Complete
• 页码：52-64
• 全文大小：1449 K

文摘

Immunotherapy for the treatment of cancer has made significant progresses over the last 20 years. Multiple efforts have been attempted to restore immune-mediated tumor elimination, leading to the development of several targeted immunotherapies. Data from recent clinical trials suggest that these agents might improve the prognosis of patients with advanced genito-urinary (GU) malignancies. Nivolumab has been the first immune checkpoint-inhibitor approved for pre-treated patients with metastatic renal cell carcinoma. Pembrolizumab and atezolizumab have shown promising results in both phase I and II trials in urothelial carcinoma. Brentuximab vedotin has demonstrated early signals of clinical activity and immunomodulatory effects in highly pre-treated patients with testicular germ cell tumors.

In this review, we have summarized the major clinical achievements of immunotherapy in GU cancers, focusing on immune checkpoint blockade as well as the new immunomodulatory monoclonal antibodies (mAbs) under clinical evaluation for these malignancies.